Dasatinib for the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia：report of ten cases and review of literature
10.3760/cma.j.issn.1009-9921.2016.10.007
- VernacularTitle:达沙替尼治疗费城染色体阳性急性淋巴细胞白血病十例并文献复习
- Author:
Dapeng PENG
;
Xudong WEI
;
Ruihua MI
;
Qingsong YIN
;
Hao AI
;
Lin CHEN
- Publication Type:Journal Article
- Keywords:
Dasatinib;
Philadelphia chromosome;
Leukemia,lymphoblastic,acute
- From:
Journal of Leukemia & Lymphoma
2016;25(10):602-606
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the clinical response and safety of second-generation tyrosine kinase inhibitor dasatinib in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph + ALL). Methods The clinical data of 10 adult Ph + ALL patients treated with dasatinib were analyzed with review of literatures. Results All the 10 Ph+ ALL patients treated with dasatinib achieved remission in 7 weeks, including 9 cases of complete remission [7 cases achieved complete molecular remission (CRm) in 13 weeks]. The median overall survival time (OS) was 13.8 months (5-33), and the median disease-free survival (DFS) time was 10.8 months (4-25). There were 3 cases of pleural effusion, 4 cases of Ⅳ degree of bone marrow suppression and 6 cases of extremely low blood platelet, which could be that was improved via by symptomatic treatment and, with no case of the death occurred during the treatment of dasatinib, the safety was high. Conclusion Dasatinib can deepen molecular biological reaction and prolonged the survival time of patients in the treatment of adult Ph+ ALL, with high remission rate and safety, and which can be considered as first-line treatment.
